Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia
Hämostaseologie · 01.02.2023 · 43 (01) · 022-027
DOI: 10.1055/a-1986-1556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.02.2023. Verfasst von Günalp Uzun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Immunoassay, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Herzstiftung, German Research Foundation.
Abstract (Originalsprache)
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious complication of adenoviral vector-based COVID-19 vaccines. Similar to heparin-induced thrombocytopenia (HIT), antibodies reacting to platelet factor 4 (PF4) are responsible for platelet activation in VITT. The diagnosis of VITT includes the detection of anti-PF4 antibodies. Particle gel immunoassay (PaGIA) is one of the rapid immunoassays that is commonly used in the diagnosis of HIT to detect anti-PF4 antibodies. The aim of this study was to investigate the diagnostic performance of PaGIA in patients suspected of VITT. In this retrospective, single-center study, the correlation between PaGIA, enzyme immunoassay (EIA), and modified heparin-induced platelet aggregation assay (HIPA) in patients with findings suggestive of VITT was investigated. A commercially available PF4 rapid immunoassay (ID PaGIA H/PF4, Bio-Rad-DiaMed GmbH, Switzerland) and an anti-PF4/heparin EIA (ZYMUTEST HIA IgG, Hyphen Biomed) were used according to manufacturer's instructions. Modified HIPA was accepted as the gold standard test. Between March 8 and November 19, 2021, a total of 34 samples from clinically well-characterized patients (14 males, 20 females, mean age: 48.2 ± 18.2 years) were analyzed with PaGIA, EIA, and modified HIPA. VITT was diagnosed in 15 patients. Sensitivity and specificity of PaGIA were 54 and 67%, respectively. Anti-PF4/heparin optical density values were not significantly different between PaGIA positive and negative samples (p = 0.586). The sensitivity and specificity of EIA, on the other hand, were 87 and 100%, respectively. In conclusion, PaGIA is not reliable in the diagnosis of VITT because of its low sensitivity and specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany.
- Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany.
Förderung
- Herzstiftung
- German Research Foundation
Zitieren
APA
Uzun, G., Althaus, K., Hammer, S., Wanner, Y., Nowak-Harnau, S., Enkel, S., & Bakchoul, T. (2023). Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia. Hämostaseologie, 43(01), 022-027. https://doi.org/10.1055/a-1986-1556
Vancouver
Uzun G, Althaus K, Hammer S, Wanner Y, Nowak-Harnau S, Enkel S, et al. Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia. Hämostaseologie. 2023;43(01):022-027. doi:10.1055/a-1986-1556
BibTeX
@article{Uzun2023,
author = {Uzun, Günalp and Althaus, Karina and Hammer, Stefanie and Wanner, Yvonne and Nowak-Harnau, Stefanie and Enkel, Sigrid and Bakchoul, Tamam},
title = {Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia},
journal = {Hämostaseologie},
year = {2023},
volume = {43},
number = {01},
pages = {022--027},
doi = {10.1055/a-1986-1556}
}
EUVIMED